Jazz Pharmaceuticals Inc.

Matthew Fust has served as a member of our board of directors since 2005. Mr. Fust is the Chief Financial Officer of Jazz Pharmaceuticals, a pharmaceutical company. From May 2002 to May 2003, Mr. Fust was Chief Financial Officer at Perlegen Sciences, Inc., a biotechnology company. From June 1996 to January 2002, he was an executive with ALZA Corporation, first as Controller and then as Chief Financial Officer. Mr. Fust holds an M.B.A. from the Stanford Graduate School of Business and a Bachelor's degree in Accounting from the University of Minnesota.

Dr. Perera joined The Parkinson's Institute in January 2009 as Co- Chief Executive Officer. He is a graduate of Harvard Medical School and received his MBA from Arizona State University. He was formerly a faculty member at New York Hospital and North Shore University Hospital in New York. Dr. Perera is a board certified Psychiatrist and has divided his career between patient care and drug development. He has held positions of increasing responsibility in clinical research and management with small and large pharmaceutical companies and has been involved in the submission of numerous investigational new drug applications and their commercial launch. He is also the co-chair of the program committee of the American Society of Experimental NeuroTherapeutics.

Robert Myers joined Jazz Pharmaceuticals at its inception was appointed as Jazz Pharmaceuticals' President in March 2007. From 2003 until 2007, Mr. Myers served as Jazz Pharmaceuticals' Executive Vice President and Chief Business Officer. From 2002 until 2003, Mr. Myers served as Executive Vice President, Pharmaceuticals at Exelixis, Inc., a biotechnology company. He previously held various positions with ALZA Corporation from 1992 to 2001, most recently as its Senior Vice President, Commercial Development. In this role, he was responsible for ALZA Corporation's corporate development, mergers and acquisitions, new product planning and corporate planning. Mr. Myers received B.S. and M.S. degrees from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

Carol Gamble was appointed as Jazz Pharmaceuticals' Senior Vice President in 2004 and has served as Jazz Pharmaceuticals' General Counsel and Corporate Secretary since 2003. She is also Jazz Pharmaceuticals' Compliance Officer. From 2000 to 2002, she served as General Counsel and Corporate Secretary of Aerogen, Inc., a biopharmaceutical company acquired by Nektar Therapeutics. From 1988 to 2000, she held various positions with ALZA Corporation, most recently as its Senior Vice President and Chief Corporate Counsel. Ms. Gamble received a B.S. from Syracuse University and a J.D. from the University of California, Berkeley, Boalt Hall.

Janne Wissel has served as Jazz Pharmaceuticals' Senior Vice President of Development since 2004. From 2003 to 2004, she served as Jazz Pharmaceuticals' Vice President of Development. From 1981 to 2003, she held various positions at ALZA Corporation, most recently as its Senior Vice President, Operations, with responsibility for ALZA Corporation's global regulatory, quality, general operations and manufacturing activities. She has led the development, registration and launch of more than 20 pharmaceutical products in the neurology, pediatric psychiatry, endocrinology, urology and oncology areas. Ms. Wissel received a B.S. from the University of California, Davis and an M.B.A. from the University of Phoenix.

Janne Wissel has served as Jazz Pharmaceuticals' Senior Vice President of Development since 2004. From 2003 to 2004, she served as Jazz Pharmaceuticals' Vice President of Development. From 1981 to 2003, she held various positions at ALZA Corporation, most recently as its Senior Vice President, Operations, with responsibility for ALZA Corporation's global regulatory, quality, general operations and manufacturing activities. She has led the development, registration and launch of more than 20 pharmaceutical products in the neurology, pediatric psychiatry, endocrinology, urology and oncology areas. Ms. Wissel received a B.S. from the University of California, Davis and an M.B.A. from the University of Phoenix.

Ed Luker joined Jazz Pharmaceuticals in October 2005. Mr. Luker was most recently National Field Sales Director, Pain Management, for McNeil Consumer & Specialty Pharmaceuticals, a division of Johnson & Johnson. In this role, he led the sales launch strategy for FLEXERIL® 5mg. Previously, he held various roles at ALZA Corporation, including Area Business Director of CNS, where he co-led the salesforce which launched CONCERTA®. Prior to joining ALZA, Mr. Luker served in various sales and marketing management positions with VIVUS, Inc., where he helped build the launch team for MUSE®; International Rehabilitative Sciences and Syntex Laboratories. He holds a Bachelor of Science degree from the University of California, Davis.

Felissa Cagan joined Jazz Pharmaceuticals as its Vice President, Intellectual Property in March 2004. Prior to joining Jazz, she was Senior Director, Intellectual Property, at Nektar Therapeutics (formerly Inhale Therapeutic Systems) beginning in March 1997. Ms. Cagan was patent counsel at ALZA Corporation from 1994 to 1997. Prior to joining ALZA, she was an associate with the law firm of Morrison & Foerster. Ms. Cagan received her J.D. from the Santa Clara University School of Law and a B.S. in Chemical Engineering from Northwestern University. She is a registered Professional Engineer in the State of California and was a practicing Chemical Engineer for seven years prior to attending law school.

Jason Levin has been responsible for Licensing & Acquisitions since joining Jazz Pharmaceuticals in May 2003. Mr. Levin brings more than 15 years of experience in the life sciences industry. Prior to joining Jazz Pharmaceuticals, Mr. Levin served as Director, Business Development at ALZA Corporation, a wholly owned subsidiary of Johnson and Johnson. In this role, Mr. Levin participated in ALZA's drug delivery technology in-licensing and out-licensing efforts. Previously, he was responsible for business development at an early stage medical diagnostics company in Austin, Texas, following four years in The Woodlands, Texas as a scientist at GeneMedicine, Inc. (now Valentis, Inc.)

Julie Anne Smith joined Jazz Pharmaceuticals as Vice President, Marketing in August 2006. Ms. Smith comes to the company with more than 13 years of experience in healthcare, having served most recently as an executive at Genzyme Corporation since 2001 as Vice President, Global Marketing and Vice President, Product Strategy and Development. Prior to joining Genzyme, Ms. Smith helped to establish the commercial team at Novazyme Pharmaceuticals, a biotech start-up company specializing in orphan drugs. Ms. Smith began her career in the pharmaceutical industry at Bristol-Myers Squibb Company, where she held marketing positions of increasing responsibility in oncology and neurology. Previously she conducted clinical research at Massachusetts General Hospital in neuroendocrinology. She holds a Bachelor of Science degree from Cornell University.

Mark G. Eller joined Jazz Pharmaceuticals as its Vice President, Research, in May 2005. Prior to joining Jazz Pharmaceuticals, he was Vice President, Clinical Pharmacology at Quintiles, a position he held since January 2001. From 1988 until joining Quintiles, Dr. Eller served in positions of increasing responsibility at Hoechst Marion Roussel (now Sanofi-Aventis). Prior to joining HMR, he held positions with The Upjohn Company and the University of Cincinnati College of Pharmacy. Dr. Eller holds a Ph.D. in Pharmaceutics from The University of Iowa and received his B.S. in Pharmacy from The University of Iowa College of Pharmacy.

Michael DesJardin joined Jazz Pharmaceuticals in July 2004 as Vice President, Product Development, with over 25 years of industry experience. Mr. DesJardin previously served in positions of increasing responsibility at ALZA Corporation starting in 1995, most recently as Executive Director for Implant R&D. In addition, Mr. DesJardin worked for 15 years in chemical development, with several assignments in API manufacturing at Dow Chemical and Marion Merril Dow. Mr. DesJardin has led technical development and commercial manufacturing for chemical and pharmaceutical products which incorporated several drug delivery technologies, including oral, implantable, and injection systems. Mr. DesJardin received a Bachelor of Science in Chemical Engineering from the University of California, Berkeley and is a registered Professional Engineer in the State of California.

Nandan Oza joined Jazz Pharmaceuticals as Vice President, Manufacturing and Supply Chain Operations in February 2007. Prior to joining Jazz Pharmaceuticals, he was Vice President, Manufacturing and Supply Chain Operations at Connetics Corporation beginning in 2003. From 1988 through 2003, he was at ALZA Corporation, most recently as Executive Director, Bay Area Operations. Mr. Oza received his B.S. degree in Engineering from the University of Houston and pursued graduate engineering studies at the University of California at Davis. He received his MBA from National University in San Diego.